Esthesioneuroblastoma: Multimodal management and review of literature

Ritesh Kumar

Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory neuroepithelium, including the superior one third of the nasal septum, cribiform plate, and superior turbinates, extending to base of the skull and to the intracranial space[1]. ENB was first described by Berger et al[2] in 1924. Because of uncertainty regarding the precise histological origin of the tumour, it has been described using various names in the literature, but the commonly used terms in recent publications are ENB and olfactory neuroblastoma. It constitutes only 3% of all intranasal neoplasms and its etiology remains unclear[3]. ENB manifests across all ages, with peaks in the second and sixth decades of surgery, chemotherapy and radiotherapy. Multimodality approach with a risk-adapted strategy is required to achieve good control rates while minimizing treatment related toxicity.

Key words: Surgery; Radiotherapy; Chemotherapy; Esthesioneuroblastoma

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: This article is a comprehensive review of literature of a rare and aggressive neoplasm. This article outlines the various newer details of diagnosis, staging and treatment aspects of esthesioneuroblastoma (ENB). The importance of multimodality approach in management of ENB is reviewed in detail.

Kumar R. Esthesioneuroblastoma: Multimodal management and review of literature. World J Clin Cases 2015; 3(9): 774-778 Available from: URL: http://www.wjgnet.com/2307-8960/full/v3/i9/774.htm DOI: http://dx.doi.org/10.12998/wjcc.v3.i9.774

INTRODUCTION

Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory neuroepithelium, including the superior one third of the nasal septum, cribiform plate, and superior turbinates, extending to base of the skull and to the intracranial space[1]. ENB was first described by Berger et al[2] in 1924. Because of uncertainty regarding the precise histological origin of the tumour, it has been described using various names in the literature, but the commonly used terms in recent publications are ENB and olfactory neuroblastoma. It constitutes only 3% of all intranasal neoplasms and its etiology remains unclear[3]. ENB manifests across all ages, with peaks in the second and sixth decades of
CLINICAL PRESENTATION
ENB have varying biological behaviour, ranging from slow indolent growth to a highly aggressive neoplasm with rapid widespread metastasis resulting in poor survival. The most common presentation is unilateral nasal obstruction followed by epistaxis. Other clinical features develops with local spread of tumor like proptosis (infiltration into orbital canal), cranial nerve palsies (infiltration into cranial foramens and brain), swelling in neck (neck nodes) and metastatic symptoms.

PATHOLOGY
Light microscopy features consists of homogeneous small cells having uniform round nuclei, dense core neurosecretory granules, neuronal processes with microtubules and neurofilaments, and rare synapses. The closest histopathological differential diagnosis is neuroblastoma. The neuroblastoma stains positive for NSE, synaptophysin, Leu7, and neurofilament protein. Elevated serum catecholamines are also suggestive of neuroblastoma.

INVESTIGATIVE WORK-UP
The gold standard of diagnosis is biopsy of the lesion showing characteristic histopathological features along with IHC. Fine needle aspiration cytology of suspected lymph nodes in neck is recommended to rule out nodal spread. Local extension of the tumor is evaluated using contrast enhanced computed tomography (CECT) of the face and neck (Figure 1). Magnetic resonance imaging (MRI) is better in evaluating sinonasal, intraorbital or intracerebral extension (Figure 2). As computed tomography (CT) can better demonstrate bony erosions, both studies are usually required in most of the patients. Chest X-ray, ultrasound abdomen and CECT chest and abdomen is helpful in detecting systemic metastasis. Baseline hemogram, renal function tests and liver function tests are done for further treatment planning. Positron emission tomography is not routinely recommended for staging evaluation but can be used as an adjunct to CT and MRI.

STAGING
Tumor staging is an important guide for prognosis and therapy. Several staging systems, including Hyman, Kadish, and tumor, node, metastasis (TNM) systems, have been proposed as a guide to choosing treatment modalities. Staging for ENB was first proposed by Kadish et al and the tumors were staged as three group categories. Group A is limited to tumors of the nasal cavity; group B is extension to the paranasal sinuses; and group C is extension beyond the paranasal sinuses and nasal cavity. Morita et al in 1993 published a revised Kadish system that redefined stage C (consisting of local disease spreading beyond the paranasal sinuses) and included a stage D (distant metastasis) (Table 2). In 1992, Dulguerov et al proposed TNM staging system based on the TNM system, determined on pre-treatment CT and MRI findings (Table 3). However, modified Kadish staging system is the most widely used staging system.

---

Table 1  Hyams histopathological grading

| Grade | Lobular architecture preservation | Mitotic index | Nuclear polymorphism | Fibrillary matrix | Rosettes | Necrosis |
|-------|----------------------------------|---------------|----------------------|------------------|---------|----------|
| I     | *                               | Zero          | None                 | Prominent        | HW rosettes | None     |
| II    | *                               | Low           | Low                  | Present          | HW rosettes | None     |
| III   | */-                             | Moderate      | Moderate             | Low              | FW rosettes | Rare     |
| IV    | */-                             | High          | High                 | Absent           | None      | Frequent |

---

Figure 1  Axial computed tomography scan showing locally advanced esthesioneuroblastoma with extension to paranasal sinus and orbit.

leucocytic common antigen. Electron microscopy is reliable in visualising uniform round nuclei, dense core neurosecretory granules, neuronal processes with microtubules and neurofilaments, and rare synapses. The closest histopathological differential diagnosis is neuroblastoma. The neuroblastoma stains positive for NSE, synaptophysin, Leu7, and neurofilament protein. Elevated serum catecholamines are also suggestive of neuroblastoma.
The various treatment modalities used in the management of ENB are surgery, chemotherapy, radiation therapy (RT) and palliative care. Nowadays, the multimodal approach is recommended for improved survival and quality of life of the patients.

**Surgery**
The mainstay of the treatment is surgery. The advantage of surgery is tumor removal, immediate improvement in compressive symptoms, proper tissue for histopathological and prognostic evaluation. Intracranial extension and close proximity to the cribriform plate and ethmoidal roof requires a combined transfacial and neurosurgical approach. For T1 tumors, craniotomy is not justified when there is clear radiological evidence of a normal cribriform plate and upper ethmoid cells. All other patients should be managed by combined craniofacial approach. Dulguerov et al.\(^5\) showed 100% local control with craniofacial resection as compared to 40% local control with other surgical resections. Similarly, Spaulding et al.\(^2\) at the University of Virginia showed reduction of 20% local recurrence rate with the craniofacial resection as compared to non-craniofacial approach. An international collaborative study of 17 centres reported the role of craniofacial resection in ENB in 2012. Five-year overall survival was 78% and 5-year recurrence-free survival was 64%\(^4\). Craniofacial resection allows en bloc resection of the tumour with better assessment of intracranial extension and protection of the brain and optic nerves. The current accepted practice is open or endoscopic craniofacial surgical resection.

**RT**
Specimens from the nasal cavity and paranasal sinuses, even en bloc, are difficult to orient, and surgical margins are difficult to analyze properly. Due to locally infiltrative nature of the disease, surgically clear margins are difficult to achieve. Thus there is a role of adjuvant RT to minimize the risk of local recurrence.\(^\text{12,15}\) Adjuvant RT is indicated for Kadish stage B and C, whereas Kadish A disease can be managed with surgery alone. RT is delivered to the tumor bed and local extension with nodal irradiation reserved for involved nodes. Elective nodal irradiation is not practiced routinely. The RT doses have varied from 50 to 60 Gy in the literature.\(^\text{16,17}\) With higher RT doses, there is always a risk of long term neural toxicity. But with advancement in technologies in delivery of RT with Intensity modulated RT (IMRT), Image guided RT and proton therapy, the long term neural toxicities can be minimized. RT is also used in neoadjuvant settings in locally advanced tumors and in palliation in metastatic settings. In small local recurrences, stereotactic radiosurgery and stereotactic radiotherapy can be used even for re-radiation.\(^\text{18}\).

**Chemotherapy**
The role of chemotherapy is not very clear in adjuvant settings in early tumors, but in locally advanced and metastatic tumors it has a definitive role. It decreases the chances of systemic failure by acting on systemic micro-

---

**Table 2 Modified kadish staging**

| Stage | Description |
|-------|-------------|
| A     | Tumour limited to the nasal fossa |
| B     | Tumour extension into the paranasal sinuses |
| C     | Tumour extension beyond the paranasal sinuses and nasal cavity |
| D     | Distant metastasis |

**Table 3 Tumor, node, metastasis staging system**

| Stage | Description |
|-------|-------------|
| T1    | Tumour involving the nasal cavity and/or paranasal sinuses (excluding sphenoid), sparing the most superior ethmoidal cells |
| T2    | Tumour involving the nasal cavity and/or paranasal sinuses (including the sphenoid) with extension to or erosion of the cribiform plate |
| T3    | Tumour extending into the orbit or protruding into the anterior cranial fossa, without dural invasion |
| T4    | Tumour involving the brain |
| N0    | No cervical lymph-node metastasis |
| N1    | Any form of cervical lymph-node metastasis |
| M0    | No metastases |
| M1    | Distant metastasis |

---

Figure 2 T1 W sagital section (A) and axial section (B) magnetic resonance imaging showing locally advanced esthesioneuroblastoma. Reprinted with permission from medscape drugs and diseases (http://emedicine.medscape.com/), 2015, Available from: URL: http://emedicine.medscape.com/article/250237-overview.
metastasis\textsuperscript{[19]}. In neoadjuvant settings, it decreases the size of tumor, decreases compressive symptoms and helps in further complete removal of the tumour. It can be combined with RT in both neoadjuvant and adjuvant settings for better results\textsuperscript{[20]}. The common drugs used are cisplatin, etoposide, adriamycin, vincristine and cyclophosphamide. Initial literature in support of neoadjuvant CT (NACT) comes from the University of Virginia, where Kadish C stage patients received 2 cycles of NACT with vincristine and cyclophosphamide with or without doxorubicin, followed by RT dose of 50 Gy, followed by craniofacial resection\textsuperscript{[21]}. The 5-year and 10-year actuarial survival was 72% and 60% respectively. Subsequently, Cisplatin-based regimens became the preferred CT regimen in ENB at the Mayo Clinic, Gustave-Roussy Institute and Harvard Medical Institute\textsuperscript{[22-24]}. Presently, the preferred chemotherapy regimen is cisplatin (33 mg/m\textsuperscript{2} daily) and etoposide (100 mg/m\textsuperscript{2} daily) for 3 Da.

Management of neck

Neck metastases at presentation in seen in 5% of patients\textsuperscript{[25]}. In such patients, neck should be addressed by neck dissection or radiotherapy. Delayed neck metastases has been reported in 16% of patients in older series\textsuperscript{[25]}. But with newer investigative, surgical, CT and RT techniques, these incidences are better managed. Patients with advanced local disease should be evaluated radiologically for neck metastases and regional treatment in form of neck dissection or neck RT should be offered in case of positive neck nodes.

STAGE WISE TREATMENT

Kadish A

Surgery alone with clear margins is sufficient in Kadish A staged tumors. Adjuvant RT is indicated in close and positive margins or with residual disease. No role of adjuvant chemotherapy.

Kadish B

Surgery followed by adjuvant RT is the treatment of choice. Role of adjuvant CT is controversial. Recent reports shows use of adjuvant CT. Neoadjuvant CT or RT can be used in inoperable cases.

Kadish C

Kadish C staged tumors requires all the three modalities. Neoadjuvant approach (CT/RT/concurrent CT-RT) is preferred. Definitive role of adjuvant CT in these settings.

Kadish D

Systemic chemotherapy and palliative RT to local site and metastatic sites are advised. Palliative care should be incorporated for improving the quality of life.

RECURRENT

Local recurrence and/or distant metastases remain the main problem in the management of ENB. Salvage treatment consists of surgery, surgery and postoperative RT, RT alone, palliative chemotherapy (CCT), or supportive care. The management options depend upon the type of relapse and initial treatment received by the patient. Bachar et al\textsuperscript{[26]} reported local recurrence was documented in 30.7%, regional recurrence in 17.9%, and distant metastasis in 7.7% of patients. In a metaanalysis by Dulguerov et al\textsuperscript{[6]}, local regional, and distant recurrence rates were reported in 29%, 16%, and 17%, respectively.

PROGNOSIS

The most important prognostic factors influencing the outcome reported in ENB are Hyams grade, positive lymph nodes, Kadish stage, extent of resection and postoperative RT with atleast 54 Gy\textsuperscript{[27-29]}. 

ENB IN CHILDREN

In pediatric population upto 15 years of age, the incidence of ENB is 0.1/100000\textsuperscript{[30]}. In younger patients, the tumors have a more aggressive presentation and advanced disease. Bisogno et al\textsuperscript{[31]} reported 9 young patients of ENB managed with combined modality approach. The 5-year progression-free survival and overall survival were 77.8% and 88.9% respectively\textsuperscript{[31]}. El Kababri et al\textsuperscript{[31]} reported 11 children and adolescents treated with combined modality approach between 1982 and 2002. The 5-year actuarial disease-free survival and overall survival rate was 91% with ten patients being long term survivors\textsuperscript{[32]}. Thus, pediatric ENB has an aggressive presentation but has good clinical results with combined modality approach.

CONCLUSION

Most of the patients of ENB present in locally advanced stage and the optimal management depends on the cooperation between clinicians, surgeons, radiologists and pathologists from establishing diagnosis to organizing the therapeutic strategy. Novel strategies including combined CCT with RT and/or dose escalation with advanced RT techniques such as IMRT and proton therapy should be prospectively investigated to improve the survival results in ENB.

REFERENCES

1. Levine PA, McLean WC, Cantrell RW. Esthesioneuroblastoma: the University of Virginia experience 1960-1985. Laryngoscope 1986; 96: 742-746 [PMID: 3724324]
2. Berger L, Luc R, Richard D. L’esthesioneuroepitheliome olfactif. Bull Assoc Fr Etude Cancer 1924; 13: 410-421
3. Kumar M, Fallon RJ, Hill JS, Davis MM. Esthesioneuroblastoma in children. J Pediatr Hematol Oncol 2002; 24: 482-487 [PMID: 12218596]
4. Elkon D, Hightower SI, Lim ML, Cantrell RW, Constable WC. Esthesioneuroblastoma. Cancer 1979; 44: 1087-1094 [PMID: 383268]
5. Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA
experience 1970-1990. Laryngoscope 1992; 102: 843-849 [PMID: 1495347]

6. Dulguerov P, Allal AS, Calcutta TC. Esthesioneuroblastoma: a meta-analysis and review. Lancer Oncol 2001; 2: 683-690 [PMID: 11902539]

7. Hirose T, Scheithauer BW, Lopes MB, Gerber HA, Altermatt HJ, Harner SG, VandenBerg SR. Olfactory neuroblastoma. An immunohistochemical, ultrastructural, and flow cytometric study. Cancer 1995; 76: 4-19 [PMID: 8630875]

8. Hyams VJ. Olfactory neuroblastoma. In: Hyams VJ, Baksakis JG, Michaels L. Tumors of the upper respiratory tract and ear. Washington DC: Armed Forces Institute of Pathology, 1988: 240-248

9. Pickuth D, Heywang-Kobrunner SH, Spielmann RP. Computed tomography and magnetic resonance imaging features of olfactory neuroblastoma: an analysis of 22 cases. Clin Otolaryngol Allied Sci 1999; 24: 457-461 [PMID: 10542931]

10. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37: 1571-1576 [PMID: 1260676]

11. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 33: 706-714; discussion 714-715 [PMID: 8492845]

12. Díaz EM, Johinagan RH, Pero C, El-Naggak AG, Roberts DB, Barker JL, DeMonte F. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 2005; 27: 138-149 [PMID: 15654688]

13. Spaulding CA, Krananyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: a comparison of two treatment eras. J Radiat Oncol Biol Phys 1988; 15: 581-590 [PMID: 3138210]

14. Patel SG, Singh B, Stambuk HE, Carlion D, Bridger PG, Cantu G, Cheesman AD, Donald P, Fliss D, Gullane P, Janecka I, Kowlalski LP, Kraus DH, Levine PA, Medina LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurosurg B Skull Base 2012; 73: 208-220 [PMID: 23730550 DOI: 10.1067/s-0032-1311754]

15. Gruber G, Laedrauch K, Baumert B, Caversaccio M, Raveh J, Greiner R. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002; 54: 486-491 [PMID: 12243826]

16. Slevin NJ, Irwin CJ, Banerjee SS, Gupta NK, Farrington WT. Olfactory neural tumours—the role of external beam radiotherapy. J Laryngol Otol 1996; 110: 1012-1016 [PMID: 8944873]

17. Platek ME, Merziana M, Mashali TR, Popat SR, Rigual NR, Warren GW, Singh AK. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol 2011; 6: 41 [PMID: 21518449 DOI: 10.1186/1748-717x-6-41]

18. Van Gompel JJ, Carlson ML, Pollock BE, Moore AH, Foote RL, Link MJ. Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma. Neurosurgery 2013; 72: 332-339; discussion 339-340 [PMID: 23208068 DOI: 10.1227/ NEU.0b013e31827ed2c2]

19. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, Mofinhan TJ, Buckner JC. Retrospective review of adjuvant therapy for esthesioneuroblastoma. J Neurooncol 2008; 90: 201-204 [PMID: 18633576 DOI: 10.1007/s11060-008-9645-y]

Kumar R. Esthesioneuroblastoma: Multimodal management

10. Kadish S, Goodman M, Wang CC. Olfactory neuroblastoma. A clinical analysis of 17 cases. Cancer 1976; 37: 1571-1576 [PMID: 1260676]

11. Morita A, Ebersold MJ, Olsen KD, Foote RL, Lewis JE, Quast LM. Esthesioneuroblastoma: prognosis and management. Neurosurgery 1993; 33: 706-714; discussion 714-715 [PMID: 8492845]

12. Díaz EM, Johinagan RH, Pero C, El-Naggak AG, Roberts DB, Barker JL, DeMonte F. Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck 2005; 27: 138-149 [PMID: 15654688]

13. Spaulding CA, Krananyak MS, Constable WC, Stewart FM. Esthesioneuroblastoma: a comparison of two treatment eras. J Radiat Oncol Biol Phys 1988; 15: 581-590 [PMID: 3138210]

14. Patel SG, Singh B, Stambuk HE, Carlion D, Bridger PG, Cantu G, Cheesman AD, Donald P, Fliss D, Gullane P, Kamata SE, Janecka I, Kowlalski LP, Kraus DH, Levine PA, Medina LR, Pradhan S, Schramm V, Snyderman C, Wei WI, Shah JP. Craniofacial surgery for esthesioneuroblastoma: report of an international collaborative study. J Neurosurg B Skull Base 2012; 73: 208-220 [PMID: 23730550 DOI: 10.1067/s-0032-1311754]

15. Gruber G, Laedrauch K, Baumert B, Caversaccio M, Raveh J, Greiner R. Esthesioneuroblastoma: irradiation alone and surgery alone are not enough. Int J Radiat Oncol Biol Phys 2002; 54: 486-491 [PMID: 12243826]

16. Slevin NJ, Irwin CJ, Banerjee SS, Gupta NK, Farrington WT. Olfactory neural tumours—the role of external beam radiotherapy. J Laryngol Otol 1996; 110: 1012-1016 [PMID: 8944873]

17. Platek ME, Merziana M, Mashali TR, Popat SR, Rigual NR, Warren GW, Singh AK. Improved survival following surgery and radiation therapy for olfactory neuroblastoma: analysis of the SEER database. Radiat Oncol 2011; 6: 41 [PMID: 21518449 DOI: 10.1186/1748-717x-6-41]

18. Van Gompel JJ, Carlson ML, Pollock BE, Moore AH, Foote RL, Link MJ. Stereotactic radiosurgical salvage treatment for locally recurrent esthesioneuroblastoma. Neurosurgery 2013; 72: 332-339; discussion 339-340 [PMID: 23208068 DOI: 10.1227/NEU.0b013e31827ed2c2]
